Market cap
$602,555

Virax Biolabs Group Limited (VRAX) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for VRAX, including 3 SEC filings, 1 insider trade and 1 leadership change. The most recent was published Nov 18, 2026.

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.

Financial highlights

Full financials
Revenue, FY2026
$12.4K
Revenue growth
+96.2%
Net income, FY2026
-$5.02M
Net margin
-40439.1%
Free cash flow, FY2026
-$4.88M
Cash
$6.44M

For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.

News · 26 weeks27+100%
2026-05-24: 22026-05-31: 02026-06-07: 12026-06-14: 02026-06-21: 22026-06-28: 02026-07-05: 72026-07-12: 22026-07-19: 12026-07-26: 12026-08-02: 02026-08-09: 02026-08-16: 12026-08-23: 12026-08-30: 32026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 12026-10-11: 02026-10-18: 12026-10-25: 22026-11-01: 02026-11-08: 12026-11-15: 1
2026-05-242026-11-15
Mix1090d
  • SEC Filings7(70%)
  • Other1(10%)
  • Insider1(10%)
  • Leadership1(10%)
Activity · 52 weeks5132 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

VRAX FAQ

11 questions
  • What does Virax Biolabs Group Limited do?
    Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that...
  • What is the latest news on VRAX?
    In the last 30 days Quantisnow tracked 5 wire items for VRAX: 3 SEC filings, 1 insider trade and 1 leadership change. The most recent was published on November 18, 2026.
  • What is VRAX revenue?
    Virax Biolabs Group Limited (VRAX) reported $12.4K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 96.2% from the year before.
  • Is VRAX profitable?
    No. Virax Biolabs Group Limited reported a net loss of $5.02M for fiscal 2026 (ended Mar 31, 2026).
  • How much cash and debt does VRAX have?
    Virax Biolabs Group Limited reported $6.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does VRAX stock trade?
    Virax Biolabs Group Limited (VRAX) is listed on NASDAQ.
  • What sector and industry is VRAX in?
    Virax Biolabs Group Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.
  • When did Virax Biolabs Group Limited go public?
    Virax Biolabs Group Limited (VRAX) completed its IPO in 2022.
  • What are analysts saying about VRAX?
    Virax Biolabs Group Limited has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $3.00 price target on 2025-03-31. Recent price targets cluster around $3.00.
  • What companies are similar to VRAX?
    Notable peers in the same industry include ABT (Abbott Laboratories), CODX (Co-Diagnostics Inc.), OSUR (OraSure Technologies Inc.), QDEL (QuidelOrtho Corporation). Compare VRAX side-by-side with any of them on Quantisnow.
  • How can I track VRAX on Quantisnow?
    Quantisnow aggregates Virax Biolabs Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRAX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change